RxCelerate acquires specialist bioanalytical CRO Total Scientific Ltd

Cambridge, UK and Cambridge, MA – 30th April 2018, 1pm BST

The out-sourced drug development company, RxCelerate Ltd, announced today that it has completed the acquisition of Cambridge-based specialist bioanalytical contract research organisation, Total Scientific Ltd.

RxCelerate, which has offices in Cambridge, MA and Cambridge, UK, provides bespoke drug development services to clients ranging from virtual biotech companies to global pharmaceutical giants. Its unique model is built around out-sourcing drug development expertise rather than practical experimental work, allowing RxCelerate to guide projects from discovery through to the clinic as efficiently as possible.

Total Scientific was founded in 2006, on the Babraham Research Campus, and specialises in measuring complex drugs and proteins in biological samples, compliant with Good Laboratory Practice (GLP).

“Total Scientific was the first company in the world to offer Phenome-wide Association Studies (PheWAS) as a commercial service, underpinning their status as global leaders in highly specialised bioanalysis” said Dr Jill Reckless, CEO of RxCelerate. “This capability, coupled with their GLP-compliant bioanalysis platform significantly extends the range of cutting-edge capabilities available to our clients to move their projects more efficiently to the next value inflection point.”

Dr David Mosedale, Founder and Chief Scientist at Total Scientific, said “We built a fantastic team at Total Scientific over the last ten years, who have solved many challenging problems for our clients. But the opportunity to become part of the RxCelerate group with their global reach into US markets, allowing even more drug developers to benefit from services like PheWAS, which we have pioneered, was simply too good to pass up.”

Total Scientific currently has 11 employees, bringing the total staff at RxCelerate to 37. The Total Scientific brand will be retired with immediate effect, with all services continuing to be offered through RxCelerate. Existing clients will be contacted directly, but will see no changes in the delivery of their projects during the transition. No financial details of the transaction have been released.

“RxCelerate is one of the fastest growing companies in the UK” said Founder and Chairman, Dr David Grainger. “Adding the unique capabilities of Total Scientific to the platform will further cement our reputation as a global leader in out-sourced drug development.”


About RxCelerate

RxCelerate is an out-sourced drug discovery and development company, founded in Cambridge UK in 2012, with a focus on working smarter. It has grown rapidly to become one of the leading providers of drug development services in the United Kingdom. RxCelerate operates a unique model, providing capabilities to discover and develop drugs for clients, designing as well as executing every aspect of the research and development plan.

RxCelerate offers a wide range of services. The biology team specializes in in vivo pharmacology, offering proprietary models of wide range of human diseases, as well as complex cell-based assays. The chemistry team provides medicinal chemistry, including in silico screening, and synthesis that integrates seamlessly with the in vitro testing capability. A dedicated team designs the optimum discovery or development strategy for each project, as well as integrated program management. By working closely together, these teams can deliver pharma-grade drug product candidates at a fraction of the cost of traditional approaches.

For more information, please visit us at rxcelerate.com and connect with us on Twitter (@RxCelerate).

Contact our UK headquarters: caroline@rxcelerate.com Tel: +44 (0)1223 839557.

Contact our US headquarters: laura@rxcelerate.com Tel: +1 (857) 409-6028

About Babraham Research Campus

Babraham Bioscience Technologies Ltd (BBT) is responsible for the commercial development of the Babraham Research Campus.  The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation.  The Campus provides companies laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster. Website: www.babraham.com

For more information, please contact:

Derek Jones, Chief Executive, Babraham Bioscience Technologies Limited.

Email: derek.jones@babraham.co.uk   Tel: +44 (0)1223 496262